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A BS TR AC T
BACKGROUND
The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchro-
nization Therapy (MADIT-CRT) showed that early intervention with cardiac-resyn-
chronization therapy with a defibrillator (CRT-D) in patients with an electrocardio-
graphic pattern showing left bundle-branch block was associated with a significant 
reduction in heart-failure events over a median follow-up of 2.4 years, as compared 
with defibrillator therapy alone.
METHODS
We evaluated the effect of CRT-D on long-term survival in the MADIT-CRT popula-
tion. Post-trial follow-up over a median period of 5.6 years was assessed among all 
1691 surviving patients (phase 1) and subsequently among 854 patients who were 
enrolled in post-trial registries (phase 2). All reported analyses were performed on 
an intention-to-treat basis.
RESULTS
At 7 years of follow-up after initial enrollment, the cumulative rate of death from any 
cause among patients with left bundle-branch block was 18% among patients ran-
domly assigned to CRT-D, as compared with 29% among those randomly assigned to 
defibrillator therapy alone (adjusted hazard ratio in the CRT-D group, 0.59; 95% 
confidence interval [CI], 0.43 to 0.80; P<0.001). The long-term survival benefit of 
CRT-D in patients with left bundle-branch block did not differ significantly according 
to sex, cause of cardiomyopathy, or QRS duration. In contrast, CRT-D was not associ-
ated with any clinical benefit and possibly with harm in patients without left bundle-
branch block (adjusted hazard ratio for death from any cause, 1.57; 95% CI, 1.03 to 
2.39; P = 0.04; P<0.001 for interaction of treatment with QRS morphologic findings).
CONCLUSIONS
Our findings indicate that in patients with mild heart-failure symptoms, left ventricu-
lar dysfunction, and left bundle-branch block, early intervention with CRT-D was 
associated with a significant long-term survival benefit. (Funded by Boston Scientific; 
ClinicalTrials.gov numbers, NCT00180271, NCT01294449, and NCT02060110.)
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The Multicenter Automatic Defi-brillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) 
showed the safety and effectiveness of cardiac-
resynchronization therapy (CRT) with a defibrilla-
tor (CRT-D) in patients with asymptomatic or mild-
ly symptomatic heart failure, a reduced ejection 
fraction, and a prolonged QRS duration.1 The 
study showed that treatment with CRT-D was as-
sociated with a 34% relative reduction in the risk 
of nonfatal heart-failure events or death from any 
cause, as compared with implantable cardioverter–
defibrillator (ICD) therapy alone over a median 
follow-up period of 2.4 years. The benefit of 
CRT-D in the trial was primarily driven by a sig-
nificant relative reduction of 41% in the risk of 
nonfatal heart-failure events1 and was subse-
quently shown to be restricted to patients with 
an electrocardiographic (ECG) pattern showing 
left bundle-branch block.2 Thus, questions re-
garding the ability of CRT to reduce mortality 
among patients with asymptomatic or mildly 
symptomatic heart failure remained unanswered. 
In the present study, we prospectively assessed 
the long-term outcome of the patients enrolled in 
MADIT-CRT.
ME THODS
STUDY POPULATION
The design, protocol, and results of MADIT-CRT 
have been published previously.1,3 Briefly, 1820 
patients with ischemic cardiomyopathy (New York 
Heart Association [NYHA] functional class I or II) 
or nonischemic cardiomyopathy (NHYA function-
al class II only), a left ventricular ejection fraction 
of 30% or less, and a prolonged QRS duration 
(≥130 msec) were randomly assigned in a 3:2 ratio 
to receive CRT-D or ICD therapy. All eligible pa-
tients met the guideline criteria for ICD therapy. 
Of the 1820 patients who were enrolled in 
MADIT-CRT, 1271 (70%) were enrolled at 88 cen-
ters in the United States, and 549 (30%) were en-
rolled at 24 centers in Europe, Israel, and Canada.
DATA ACQUISITION AND PATIENT FOLLOW-UP
MADIT-CRT was carried out from December 22, 
2004, through June 22, 2009. After the publica-
tion of the primary results,1 post-trial follow-up 
was conducted for all 1691 surviving study par-
ticipants until September 10, 2010 (phase 1 of the 
extended follow-up). After September 10, 2010, 
ongoing patient follow-up (phase 2) was conducted 
at the 48 U.S. centers that agreed to participate in 
the long-term follow-up requested by the Food and 
Drug Administration for patients enrolled in the 
United States (coordinated by the Heart Research 
Follow-up Program at the University of Rochester 
Medical Center, Rochester, New York) and at 23 of 
the 24 non-U.S. centers (coordinated by the Israeli 
Association for Cardiovascular Trials at Sheba 
Medical Center, Tel Hashomer, Israel), in volving a 
total of 854 patients. A total of 40 U.S. centers 
declined to participate in the phase 2 registry.
The clinical characteristics of the patients who 
enrolled and those who did not enroll in phase 2 
of the post-trial follow-up are shown in Table S1 
in the Supplementary Appendix, available with 
the full text of this article at NEJM.org. Both 
phases of the post-trial follow-up were approved 
by the institutional review board at each partici-
pating center, and all the patients provided writ-
ten informed consent. The numbers of patients 
enrolled in the trial and in the post-trial follow-
up phases are shown in Figure 1.
All the authors were involved in the study 
design, data collection, and analysis; participated 
in the writing of the manuscript; and made the 
decision to submit the manuscript for publication. 
The commercial sponsor had no role in the study 
design, data accrual or analysis, or manuscript 
preparation or review. All the authors vouch for 
the accuracy and completeness of the reported 
findings and for the fidelity of the study to the 
protocol.
DEFINITIONS AND END POINTS
The original MADIT-CRT protocol did not speci-
fy the evaluation of a potential differential effect 
of CRT-D with respect to QRS morphologic find-
ings at baseline (in other respects, the current 
report is true to the protocol). However, after the 
publication of the primary report,1 analyses were 
performed comparing patients who had left bun-
dle-branch block (70% of the study patients) with 
those who did not have left bundle-branch block 
(30%, including 13% with right bundle-branch 
block and 17% with an intraventricular conduc-
tion delay), which suggested that the reduced risk 
of the primary end point with CRT-D was largely, 
or even entirely, in the subgroup of patients with 
left bundle-branch block.2
On the basis of this post-trial observation, the 
analysis in the present study evaluated the dif-
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ferential effects of CRT-D according to baseline 
QRS morphologic findings — specifically, left 
bundle-branch block or no left bundle-branch 
block. Two patients with missing data regarding 
QRS pattern at enrollment were excluded from the 
present study. Thus, the final study sample in-
cluded the 1818 patients from MADIT-CRT for 
whom baseline ECG data were available.
The primary end point of the current study 
was death from any cause. Secondary end points 
included a nonfatal heart-failure event and the 
combined end point of a nonfatal heart-failure 
event or death, whichever occurred first.
STATISTICAL ANALYSIS
All analyses in the present study were carried out 
on an intention-to-treat basis (i.e., according to the 
original treatment assignment, regardless of in-
trial or post-trial crossovers). Variables were ex-
pressed as means ±SD, and categorical data were 
summarized as frequencies and percentages. The 
clinical characteristics of the patients at baseline 
were compared between the subgroups, with the 
use of the Kruskal–Wallis test for continuous 
variables and the chi-square test or Fisher’s exact 
test for dichotomous variables.
The Kaplan–Meier method was used to deter-
mine cumulative probabilities of death from any 
cause and nonfatal heart-failure events from the 
time of enrollment in MADIT-CRT through post-
trial follow-up, according to treatment group, with 
between-group comparisons of cumulative event 
rates calculated by means of the log-rank test. The 
number of patients who would need to be treated 
with CRT-D to save one life was calculated as the 
inverse of the survival difference between the two 
treatment groups at each time point.
Multivariate Cox proportional-hazards regres-
sion analyses were used to evaluate the effect of 
CRT-D on the two end points of death from any 
cause and a nonfatal heart-failure event and on 
the combined end point of a nonfatal heart-failure 
event or death (whichever came first), from the 
time of enrollment in MADIT-CRT through post-
trial follow-up. The Cox model was adjusted for 
relevant clinical covariates with the use of best-
subset regression modeling (including age, serum 
creatinine level, presence or absence of diabetes 
mellitus, cause of cardiomyopathy, left ventricu-
lar end-systolic volume, QRS duration, NYHA 
functional class 3 months before enrollment, 
and smoking status). The benefit of CRT-D thera-
py as compared with ICD therapy alone among 
patients with left bundle-branch block and those 
without left bundle-branch block was assessed by 
including a term for interaction between treatment 
and presence or absence of left bundle-branch 
block in the multivariate Cox models.
Since the assessment of the interaction be-
tween QRS morphologic findings and treatment 
was not prespecified in the original protocol, we 
also carried out a post-trial landmark analysis 
(i.e., with the follow-up time beginning on June 23, 
2009, which was after trial closure on June 22, 
2009). The landmark Cox model was adjusted 
for the same covariates listed above and for the 
term for interaction between treatment and pres-
ence or absence of left bundle-branch block.
All statistical tests were two-sided, and a P value 
of less than 0.05 was considered to indicate 
1691 Survived and were included in
 follow-up for phase 1 (June 2009)
1818 Patients were enrolled in MADIT-CRT
(study initiated December 2004)
127 Died during trial
1612 Completed phase 1
(September 2010)
79 Died during phase 1
854 Were included in follow-up for phase 2
registry (September 2010)
407 Were in U.S. registry
447 Were in non-U.S. registry
758 Were not enrolled in phase 2
Termination of extended follow-up
(September 2013)
86 Died during phase 2
Figure 1. Study Design.
The population of the present study consisted of all the patients included 
in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac 
Resynchronization Therapy (MADIT-CRT),1 with the exclusion of two pa-
tients for whom baseline electrocardiographic data regarding QRS mor-
phologic findings were not available.
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statistical significance. The P values for inter-
action are reported. Analyses were carried out 
with the use of SAS software, version 9.3 (SAS 
Institute).
R ESULT S
PATIENTS
Phase 1 of the post-trial follow-up was carried 
out from June 2009 through September 2010 and 
included all surviving patients enrolled in 
MADIT-CRT; phase 2 was conducted through 
September 2013. The median follow-up of the 
enrolled patients during the trial was 2.4 years 
(interquartile range, 1.8 to 3.2), and the median 
follow-up after the trial was 5.6 years (interquar-
tile range, 5.1 to 6.4). The clinical characteristics 
of the 854 patients who participated in phase 2 of 
the extended follow-up were similar in the ICD-
only and CRT-D groups (Table 1).
During long-term follow-up, 171 of the 1818 
patients (9%) crossed over from ICD therapy alone 
to CRT-D therapy, and 92 (5%) crossed over from 
CRT-D to ICD therapy alone. Patients who crossed 
over from ICD to CRT-D therapy had several base-
line characteristics that put them at higher risk 
than those who crossed over from CRT-D to ICD 
or those who did not cross over, including a 
higher serum creatinine level, a lower ejection 
fraction, and larger left ventricular volumes.
CRT-d IN PATIENTS WITH LEFT BUNDLE-BRANCH 
BLOCK
Kaplan–Meier estimates of death from any cause 
during the period from enrollment through 7 years 
of follow-up in the two treatment groups are 
shown in Figure 2A. The curves diverge at 1 year 
and continue to have separate paths thereafter, 
with significantly lower mortality among patients 
randomly assigned to CRT-D therapy than among 
those randomly assigned to ICD therapy alone 
(P = 0.002 by the log-rank test without adjust-
ment). Thus, at 7 years of follow-up, the cumula-
tive rate of death from any cause among patients 
with left bundle-branch block was 29% in the 
ICD-only group, as compared with 18% in the 
CRT-D group. The survival difference correspond-
ed to nine patients who would need to be treated 
with CRT-D to save one life within 7 years.
The cumulative probability of a nonfatal heart-
failure event during 7 years of follow-up was also 
significantly lower among patients randomly as-
signed to CRT-D than among those randomly 
assigned to ICD therapy alone (P<0.001 by the 
log-rank test without adjustment, for the overall 
difference during follow-up). The event rates sepa-
Table 1. Clinical, Electrocardiographic, and Echocardiographic Characteristics 
of the Patients Enrolled in Phase 2 of the Extended Follow-up.*
Characteristic
ICD-Only 
Group
(N = 327)
CRT-D  
Group
(N = 527) P Value
no. (%)
Female sex 75 (23) 128 (24) 0.65
Age ≥65 yr 158 (48) 262 (50) 0.69
Ischemic cardiomyopathy 166 (51) 279 (53) 0.54
NYHA class I 51 (16) 73 (14) 0.48
NYHA class III or IV >3 mo before 
enrollment
39 (12) 53 (10) 0.38
QRS duration <150 msec 103 (31) 164 (31) 0.91
Left ventricular ejection fraction ≤25% 210 (64) 324 (61) 0.42
Left bundle-branch block 240 (73) 394 (75) 0.66
Heart rate ≥80 beats/min 46 (14) 73 (14) 0.91
Body-mass index ≥30† 109 (33) 178 (34) 0.83
Blood urea nitrogen >25 mg/dl‡ 77 (24) 125 (24) 0.99
Serum creatinine ≥1.4 mg/dl§ 60 (18) 90 (17) 0.64
Previous CABG 76 (23) 145 (28) 0.17
Diabetes mellitus 77 (24) 152 (29) 0.10
Hypertension 207 (63) 340 (65) 0.74
Previous myocardial infarction¶ 129 (40) 223 (43) 0.47
Current smoker 39 (12) 56 (11) 0.53
Previous arrhythmia
Atrial 39 (12) 54 (10) 0.45
Ventricular 23 (7) 44 (8) 0.50
Medications
ACE inhibitor 250 (76) 420 (80) 0.26
ARB 73 (22) 104 (20) 0.36
ACE inhibitor or ARB 318 (97) 510 (97) 0.70
Amiodarone 29 (9) 34 (6) 0.19
Beta-blocker 311 (95) 498 (94) 0.70
Diuretic 233 (71) 359 (68) 0.33
* ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, 
CABG coronary-artery bypass grafting, CRT-D cardiac-resynchronization therapy 
with defibrillator, ICD implantable cardioverter–defibrillator, and NYHA New 
York Heart Association.
† The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
‡ To convert the value for blood urea nitrogen to millimoles per liter, multiply 
by 0.357.
§ To convert the value for creatinine to millimoles per liter, multiply by 88.4.
¶ Data were missing for 16 patients (8 patients in each group).
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rated at the time of enrollment, and the separa-
tion was maintained (Fig. S1 in the Supplementary 
Appendix).
The unadjusted and adjusted hazard ratios for 
death from any cause and for a nonfatal heart-
failure event among patients with and those 
without left bundle-branch block are shown in 
Table 2. For the primary analysis of death from 
any cause, the adjusted hazard ratio of 0.59 in-
dicated that there was a 41% reduction in the 
long-term risk of death among patients with left 
bundle-branch block who were randomly as-
signed to CRT-D therapy, as compared with those 
randomly assigned to ICD therapy alone. For the 
secondary end point of a nonfatal heart-failure 
event, the adjusted hazard ratio of 0.38 indicated 
a reduction in risk of 62% with CRT-D (Table 2).
The effects of CRT-D therapy on mortality 
among patients with left bundle-branch block in 
seven prespecified subgroups are shown in Fig-
ure 3. The survival benefit with CRT-D was con-
sistent in each subgroup analyzed, including pa-
tients with ischemic cardiomyopathy and those 
with nonischemic cardiomyopathy, men and 
women, and patients with a longer QRS duration 
(≥150 msec) and those with a shorter QRS dura-
tion (<150 msec); there were no significant treat-
ment-by-subgroup interactions. The survival ben-
efit provided by CRT-D in patients with left 
bundle-branch block was independent of the 
QRS duration, even when the QRS duration was 
further categorized into quartiles (Fig. S2 in the 
Supplementary Appendix).
CRT-d IN PATIENTS WITHOUT LEFT BUNDLE-BRANCH 
BLOCK
Among patients without left bundle-branch block, 
Kaplan–Meier survival analysis did not show a 
significant difference between the two treatment 
groups in the cumulative probability of death 
from any cause during the period from enrollment 
through 7 years of follow-up (P = 0.21 by the log-
rank test without adjustment) (Fig. 2B). Similarly, 
the cumulative probability of a nonfatal heart-
failure event during 7 years of follow-up did not 
differ significantly between the ICD-only group 
and the CRT-D group (P = 0.58 by the log-rank 
test without adjustment) (Fig. S3 in the Supple-
mentary Appendix).
Cox proportional-hazards regression model-
ing consistently showed a lack of benefit associ-
ated with CRT-D in patients without left bundle-
branch block, with a trend toward an increased 
risk of death observed only after multivariate 
adjustment (Table 2). The differential effect of 
CRT-D on outcomes according to QRS morpho-
logic findings was significant for all end points 
(P<0.05 for interaction of treatment with QRS 
morphologic findings, in unadjusted and adjusted 
analyses) (Table 2). The lack of a survival benefit 
associated with CRT-D in patients without left 
bundle-branch block was consistent among those 
with a longer QRS duration (≥150 msec) or a 
shorter QRS duration (<150 msec), and among 
patients with QRS morphologic findings show-
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Figure 2. Kaplan–Meier Estimates of the Cumulative Probability of Death 
from Any Cause among Patients with and Those without Left Bundle-
Branch Block.
CRT-D denotes cardiac-resynchronization therapy with defibrillator, and 
ICD implantable cardioverter–defibrillator. The insets show the same data 
on an enlarged y axis.
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ing right bundle-branch block or intraventricular 
conduction delay (Fig. S4 in the Supplementary 
Appendix).
POST-TRIAL ANALYSIS
To further validate the consistency of our find-
ings, we carried out a post-trial landmark analy-
sis (i.e., with the follow-up time beginning after 
trial closure). The landmark multivariate Cox 
model showed similar findings: among patients 
with left bundle-branch block who were alive at 
the completion of the original trial, treatment 
with CRT-D was associated with a significant 
survival benefit during the post-trial follow-up 
period, as compared with ICD therapy alone (ad-
justed hazard ratio, 0.58; 95% confidence inter-
val [CI], 0.39 to 0.87; P = 0.009); however, no cor-
responding benefit was observed in patients 
without left bundle-branch block (adjusted haz-
ard ratio, 1.31; 95% CI, 0.77 to 2.23; P = 0.32; 
P = 0.02 for interaction of treatment with QRS 
morphologic findings).
DISCUSSION
The findings of the present study provide evidence 
that early intervention with CRT-D is associated 
with a significant long-term survival benefit in 
patients with mild heart failure who have left 
ventricular dysfunction and an ECG pattern show-
ing left bundle-branch block. However, there 
were no beneficial effects on long-term outcomes 
in patients without left bundle-branch block.
Cardiac-resynchronization therapy (CRT) with 
or without a defibrillator is associated with re-
verse remodeling and has been shown to reduce 
heart-failure symptoms and rates of hospitaliza-
tion and death among patients with NYHA class 
III or IV heart failure.4-7 MADIT-CRT and the 
Resynchronization Reverses Remodeling in Sys-
tolic Left Ventricular Dysfunction (REVERSE) trial 
have shown that the echocardiographic and 
clinical benefit of CRT can be extended to the 
prevention of heart-failure progression in asymp-
tomatic and mildly symptomatic patients (those 
in NYHA class I or II) with ischemic and non-
ischemic cardiomyopathy.1,8 In these trials, the 
mean follow-up time was only 2 to 3 years, rais-
ing the question of whether the early benefits of 
CRT in this population are sustained during 
long-term follow-up.
The Resynchronization–Defibrillation for Am-
bulatory Heart Failure Trial (RAFT) showed a re-
duction in the rate of death from any cause 
among patients with mild-to-moderate heart 
failure who were treated with CRT-D.9 This study, 
in contrast to ours, also enrolled patients with 
symptoms of more advanced heart failure (NYHA 
Table 2. Hazard Ratios for End Points with CRT-D versus ICD Alone, According to the Presence or Absence of Left Bundle-Branch Block.
End Point
No. of 
Events
No. of 
Patients Left Bundle-Branch Block Non–Left Bundle-Branch Block
P Value for 
Interaction*
Hazard Ratio
(95% CI) P Value
Hazard Ratio
(95% CI) P Value
Death from any cause
Unadjusted analysis 292 1818 0.63 (0.47–0.84)  0.002 1.31 (0.87–1.96) 0.19 0.004
Adjusted analysis† 267 1681 0.59 (0.43–0.80) <0.001 1.57 (1.03–2.39) 0.04 <0.001
Nonfatal heart-failure event
Unadjusted analysis 442 1818 0.42 (0.33–0.52) <0.001 1.10 (0.79–1.53) 0.59 <0.001
Adjusted analysis† 405 1681 0.38 (0.30–0.48) <0.001 1.13 (0.80–1.60) 0.48 <0.001
Nonfatal heart-failure event 
or death
Unadjusted analysis 577 1818 0.50 (0.41–0.61) <0.001 1.21 (0.90–1.63) 0.21 <0.001
Adjusted analysis† 530 1681 0.45 (0.37–0.56) <0.001 1.27 (0.94–1.73) 0.12 <0.001
* The P value for interaction represents the likelihood that the difference between the treatment effect on patients with left bundle-branch 
block and the treatment effect on those without left bundle-branch block occurred by chance alone.
† Models were adjusted for the following covariates: age at enrollment, serum creatinine level of 1.4 mg per deciliter (120 μmol per liter) or more, 
smoking status at enrollment, presence or absence of diabetes mellitus, cause of cardiomyopathy (ischemic vs. nonischemic), left ventricular end-
systolic volume at baseline indexed by body-surface area, QRS  duration at baseline (≥150 msec vs. <150 msec), and NYHA class III or IV more 
than 3 months before enrollment (yes vs. no). Covariates were identified from a best-subset regression analysis.
The New England Journal of Medicine 
Downloaded from nejm.org at IMPERIAL COLLEGE LONDON on October 7, 2016. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 370;18 nejm.org may 1, 20141700
class III). Thus, the findings of our study extend 
the RAFT data to patients with only mild heart-
failure symptoms (NYHA class I or II) before 
device implantation.
Data from the in-trial phase of MADIT-CRT 
showed that treatment with CRT-D was associ-
ated with a pronounced reduction in the risk of 
both first and subsequent heart-failure events 
among patients with left bundle-branch block. 
There was no detectable effect regarding either 
of the two end points among patients without 
left bundle-branch block.2,10 The findings from 
the present study indicate that this treatment 
interaction was sustained during long-term fol-
low-up. The long-term survival benefit of CRT-D 
in patients with left bundle-branch block was 
consistent in each subgroup analyzed, regardless 
of sex, QRS duration, and ischemic versus non-
ischemic cause of cardiomyopathy.
The mechanism underlying the differential 
effect of CRT-D according to QRS morphologic 
finding in MADIT-CRT is not clear. We previ-
ously found that the patients in MADIT-CRT 
who had an ECG pattern that did not show left 
bundle-branch block had a significantly lower 
rate of echocardiographic response to CRT-D 
and a significant increase in the risk of ventricu-
lar tachyarrhythmic events after implantation of 
a CRT-D device, as compared with patients who 
had a pattern showing left bundle-branch 
block.11 These findings may be due to the fact 
that the spread of electrical activation in the left 
ventricular wall in patients without left bundle-
branch block is more heterogeneous than in 
those with left bundle-branch block,12,13 possi-
bly leading to a pacing-induced discrepancy of 
the wave front of the electrical activation, which 
has been shown to be associated with a poor 
prognosis.14 In the present study, the lack of a 
benefit of CRT-D in patients without left bundle-
branch block was consistent, regardless of the QRS 
duration or presence or absence of right bundle-
branch block or an intraventricular conduction 
delay. Thus, at present, our data do not support 
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Figure 3. Risk of Death from Any Cause, According to Treatment Group, in Subgroups of Patients with Left Bundle-
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Findings are based on univariate Cox proportional-hazards regression models and an interaction-term analysis. 
LVEDV denotes left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVESV left ventricular 
end-systolic volume, and NYHA New York Heart Association.
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early intervention with CRT-D in any subset of 
this population.
Our findings are limited by a possible selec-
tion bias for the patients who were enrolled in 
phase 2 of the extended follow-up. It should be 
noted, however, that nearly all the patients who 
were lost to follow-up after phase 1 were from 
the U.S. medical centers that declined to par-
ticipate in the phase 2 registry, suggesting that 
the possibility of individual patient bias is lim-
ited. It should also be noted that all the analy-
ses in the present study were carried out on an 
intention-to-treat basis, thereby minimizing the 
possibility of a survival bias related to cross-
overs that occurring during or after the in-trial 
period.
Data from the present study clearly indicate 
that CRT-D was not beneficial during long-term 
follow-up in patients without left bundle-branch 
block who were enrolled in MADIT-CRT. How-
ever, the finding regarding a possible harmful 
effect of CRT-D in this population should be 
interpreted with caution, since it was obtained 
only after multivariate adjustment and is there-
fore sensitive to covariate selection.
In conclusion, our data from the MADIT-CRT 
long-term follow-up study provide evidence that 
treatment with CRT-D is associated with a sig-
nificant long-term survival benefit in patients 
with mild heart failure who have a left ventricu-
lar ejection fraction of 30% or less and left 
bundle-branch block. However, we did not ob-
serve a clinical benefit in patients who had mild 
heart failure without left bundle-branch block.
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